Whether concurrent neoadjuvant hormonal therapy contributes to pCR rates in hormone receptor–positive/HER2-positive breast cancer is being studied in the NRG Oncology/NSABP B-52 trial (NCT02003209)67. This evidence concerns the gene ERBB2 and breast carcinoma.